Prognostic factors in patients with localized primary cutaneous melanoma

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 21, Issue 2, 2012, Pages 27-31

  Mervic, Liljana ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CUTANEOUS MELANOMA; FOLLOW UP; GENDER; HISTOPATHOLOGY; HUMAN; MITOSIS; REVIEW;

AGE FACTORS; BIOPSY, NEEDLE; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SEX FACTORS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84867602875     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10162-012-0008-1     Document Type: Review

References (42)

1. Mackie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol. 2009;20 Suppl 6:vi 1-7.
2. Elwood JM, Gallagher RP. Body site distribution of cutaneous malignant melanoma in relationship to patterns of sun exposure. Int J Cancer. 1998;78:276-80.
3. Thirlwell C, Nathan P. Melanoma-part 2: management. BMJ. 2008;337:1345-8.
4. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg. 1978;188:732-42.
5. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, et al. Evidence and interdisciplinary consense [sic]-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res. 2007;17:393-9.
6. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen OS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-34.
7. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-206.
8. Balch CM, Gershenwald JE, Soong SJ, et al. Melanoma of the skin. In: Edge SE, Byrd DR, Carducci MA, et al., editors. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2009. p. 325-44.
9. Gershenwald JE, Soong SJ, Balch CM. 2010 TNM staging system for cutaneous melanoma . . . and beyond. Ann Surg Oncol. 2010;17:1475-7.
10. Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, et al. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol. 2010;17:2006-14.
11. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-8.
12. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78:427-32.
13. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484-91.
14. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery. 1979;86:343-51.
15. Mervic L, Leiter U, Meier F, Eigentler T, Forschner A, Metzler G, et al. Sex differences in survival of cutaneous melanoma are age dependent: an analysis of 7338 patients. Melanoma Res. 2011;21:244-52.
16. Spatz A, Cook MG, Elder DE, Piepkorn M, Ruiter DJ, Barnhill RL. Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer. 2003;39:1861-5.
17. Elder DE, Gimotty PA, Guerry D. Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features. Dermatol Ther. 2005;18:369-85.
18. Scolyer RA, Shaw HM, Thompson JF, Li LX, Colman MH, Lo SK, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27:1571-6.
19. Clark WH, Jr., Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893-904.
20. Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29:2199-205.
21. Clark WH Jr. A classification of malignant melanoma in man correlated with histogenesis and biologic behavior. In: Montagna W, Hu F, editors. Advances in the biology of the skin. Vol. 8, The pigmentary system. New York: Pergamon Press; 1967. p. 621-47.
22. Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86:172-8.
23. Bernengo MG, Reali UM, Doveil GC, Cappello N, Lisa F, Moretti S. BANS: a discussion of the problem. Melanoma Res. 1992;2:157-62.
24. Garbe C, Buttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer. 1995;75:2492-8.
25. Chao C, Martin RC, Ross MI, Reintgen DS, Edwards MJ, Noyes RD, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol. 2004;11:259-64.
26. Lasithiotakis K, Leiter U, Meier F, Eigentler T, Metzler G, Moehrle M, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer. 2008;112:1795-804.
27. Malaguarnera L, Ferlito L, Di Mauro S, Imbesi RM, Scalia G, Malaguarnera M. Immunosenescence and cancer: a review. Arch Gerontol Geriatr. 2001;32:77-93.
28. Nomellini V, Gomez CR, Kovacs EJ. Aging and impairment of innate immunity. Contrib Microbiol. 2008;15:188-205.
29. Kolmel KF, Kulle B, Lippold A, Seebacher C. Survival probabilities and hazard functions of malignant melanoma in Germany 1972-1996, an analysis of 10433 patients. Evolution of gender differences and malignancy. Eur J Cancer. 2002;38:1388-94.
30. Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, et al. Gender-related differences in outcome for melanoma patients. Ann Surg. 2006;243:693-8.
31. Aase A, Bentham G. Gender, geography and socio-economic status in the diffusion of malignant melanoma risk. Soc Sci Med. 1996;42:1621-37.
32. Lasithiotakis KG, Leiter U, Eigentier T, Breuninger H, Metzler G, Meier F, et al. Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976-2001: which factors contributed? Cancer. 2007;109:1174-82.
33. Quatresooz P, Uhoda I, Fumal I, Pierard-Franchimont C, Pierard GE. Revisiting the gender-linked melanoma burden. Dermatology. 2004;209:197-201.
34. de Vries E, Nijsten TE, Visser O, Bastiaannet E, van Hattem S, Janssen-Heijnen ML, et al. Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol. 2008;19:583-9.
35. Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I, et al. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer. 2009;45:1017-27.
36. Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 1992;327:516-23.
37. Karjalainen S, Hakulinen T. Survival and prognostic factors of patients with skin melanoma. A regression-model analysis based on nationwide cancer registry data. Cancer. 1988;62:2274-80.
38. Kemeny MM, Busch E, Stewart AK, Menck HR. Superior survival of young women with malignant melanoma. Am J Surg. 1998;175:437-44.
39. Shaw HM, McGovern VJ, Milton GW, Farago GA, McCarthy WH. Malignant melanoma: influence of site of lesion and age of patient in the female superiority in survival. Cancer. 1980;46:2731-5.
40. Joosse A, de Vries E, van Eijck CH, Eggermont AM, Nijsten T, Coebergh JW. Reactive oxygen species and melanoma: an explanation for gender differences in survival? Pigment Cell Melanoma Res. 2010;23:352-64.
41. Miller JG, Mac NS. Gender and cutaneous melanoma. Br J Dermatol. 1997; 136: 657-65.
42. Richardson B, Price A, Wagner M, Williams V, Lorigan P, Browne S, et al. Investigation of female survival benefit in metastatic melanoma. Br J Cancer. 1999; 80: 2025-33.